EV/EBITDA Multiple: NewAmsterdam Pharma N.V. (NAMS)
NewAmsterdam Pharma relies on external contractors for production and testing to maintain workforce flexibility. This EV/EBITDA multiple chart on GURU.Markets reflects the market valuation, where 0.00 represents the current metric. However, geopolitics are limiting capital inflows into risk assets, and the company's success is critically dependent on the final stages of development for its cardiometabolic drugs.
newamsterdampharma.com (NAMS) - metric breakdowns and financial figures
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital NewAmsterdam Pharma|NAMS - Long-Term Debt to Equity|Short-Term Debt to Equity NewAmsterdam Pharma Company N.V.|NAMS - Company Cumulative Debt|Debt to Book Capitalization Ratio NewAmsterdam Pharma Corp|NAMS - Company Long-Term Debt|Company Short-Term Debts NewAmsterdam Pharma|Quick Liquidity newamsterdampharma.com
- net income and valuation multiples indicators:
NAMS - Net Financial Result|Expected Profit NewAmsterdam Pharma|NAMS - Price to Earnings Ratio|Future Price to Earnings NewAmsterdam Pharma|NAMS - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple NewAmsterdam Pharma Corp|NAMS - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months NewAmsterdam Pharma|NAMS - Net earnings per share for the last 12 months|Quarterly EPS earnings growth newamsterdampharma.com|NAMS - Earnings growth in current year|Net earnings per share growth forecast for next year NewAmsterdam Pharma
- issuer revenue and sales details:
Initial company analysis:NAMS (NewAmsterdam Pharma N.V.)
This metric measures the total enterprise value relative to earnings before interest, taxes, depreciation, and amortization, allowing for an assessment of the real value of assets accounting for the debt load. For NewAmsterdam Pharma (NAMS), which delegates testing to external contractors, the EV/EBITDA ratio including depreciation and debt is critical, as it reflects the efficiency of a lean patent management structure against high outsourcing costs.
Who NewAmsterdam Pharma competes with
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascendis Pharma Inc. ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics - EV/EBITDA Multiple|Company Value to EBITDA rhythmtx.com|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MTSR: Enterprise Value to Operating Income Before Depreciation Ratio|MLTX (MoonLake Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Crinetics Corp|EV/EBITDA Multiple SLNO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FOLD (amicusrx.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 89bio ETNB|Agios (AGIO) - Company Value to EBITDA|GPCR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RZLT: EV/EBITDA Multiple|LXRX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MBX Biosciences|Altimmune Inc (ALT) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aardvark Therapeutics Corp (AARD)|Enterprise Value to EBITDA Ratio Sagimet Biosciences Inc SGMT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BioAge Labs, Inc. BIOA|BMEA: Enterprise Value to Operating Income Before Depreciation|Quince - EV/EBITDA Multiple|Company Value to EBITDA Fractyl Health Inc.|VTVT (vtvtherapeutics.com) - Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Ratio Agape ATP|PLUR (Pluristem Therapeutics) - EV/EBITDA Multiple|EV/EBITDA Multiple Synlogic Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lipocine (LPCN)|Enterprise Value to EBITDA Ratio matinasbiopharma.com MTNB|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Spruce Biosciences SPRB|Total Company Value to Operating Income Before Depreciation Ratio Galecto Corporation (GLTO)|CTCX: Enterprise Value to EBITDA Ratio|lumos-pharma.com - Enterprise Value to Operating Income Before Depreciation Ratio|ONVO: EV/EBITDA Multiple|Company Value to EBITDA Radius Recycling Inc. (RDUS)
